Athira Pharma, Inc. Overview
Pro stress-test →Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's drug development pipeline includes potential first-in-class and next-generation novel small molecule drug candidates designed to promote the neurotrophic hepatocyte growth factor (HGF) system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
Strategic Profile
Pro stress-test →Athira is on track to enable dosing ALS patients in 2025. Athira continues to explore strategic alternatives focused on maximizing stockholder value after receiving topline results from its Phase 2/3 LIFT-AD clinical trial in September 2024. The company faces resource constraints and has undertaken significant cost restructuring.
Competitive Landscape
Pro stress-test →Cassava Sciences, Cognition Therapeutics, Quince Therapeutics, Alzheon, and Neuphoria Therapeutics are among 15 competitors in the neurodegenerative disease drug development space. Athira competes in a crowded market with limited resources relative to better-capitalized rivals.
Industry Context
Athira Pharma, Inc. operates in Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus.
Key facts
Founded: 2011 · Headquarters: Bothell, WA · Employees: 26 · Market cap: $16.5M